跳至主要内容

FAQ – Solvent Residue Handling Manual for Active Pharmaceutical Ingredients

 The residue of solvent in APIs is one of the key issues to be mindful of during drug manufacturing. When solvent residue exists in the APIs or formulations, it may have adverse effects on the stability, purity, and efficacy of the drugs.  Overcoming the difficulties of solvent residue in APIs involves multiple aspects, such as selecting appropriate solvents, optimizing synthesis conditions, and employing effective methods for solvent removal.  At the same time, it is essential to employ scientific testing methods to monitor and ensure that solvent residues are within acceptable limits. Establishing highly sensitive and accurate analytical detection methods is indispensable to meet international standards for residual solvent detection, thus safeguarding the safety and efficacy of medication for patients.  



Medicilon Cloud Lecture invites the head of the Process Analysis Department,  Maodun Xie to share with us the challenges and solutions regarding solvent residue in APIs during preclinical operations.

Q: Benzene is used in the second to last step of the starting material. My synthesis process for the API consists of four steps. Benzene should be able to be removed in subsequent steps of the process, resulting in a low possibility of residue in the API. Does this mean further research is unnecessary?

Maodun XieWhether further research is required depends on whether the manufacturer of the raw materials you purchase has conducted relevant studies.  If the manufacturer has conducted research according to the standards for APIs, then you may not need to conduct further research.  But if the manufacturer has not conducted relevant research, then it is still necessary to study the possibility of residue.  Generally, purchased raw materials are essentially reagent-grade, and they are rarely studied for benzene residue according to API standards. Therefore, it is highly likely that research in this area will be necessary.

Q: If the process only involves 3 types of solvents, can we directly use the method of drying and weighing loss for detection?

Maodun XieWhether to use the method of drying and weighing loss for sample detection mainly depends on whether the sample is thermally stable.  If it’s a solid sample, it’s more likely to be thermally stable. In ICH-Q3C, drying and weighing loss can be used for detection, with a limit requirement of less than 0.5%.  However, it is recommended to choose the methods with stronger specificity and higher accuracy for confirmation. If the results from testing representative batches are similar to the results from drying and weighing loss, then drying and weighing loss can be used for testing in subsequent production.

Q: Can LD50 be used to calculate limits?

Maodun Xie: This is not possible. The National Medical Products Administration stated clearly in 2022 that LD50 values cannot be used in limit setting. LD50 represents the median lethal dose, indicating high toxicity and therefore cannot be used to calculate safe limits.


Analytical Testing Center

Medicilon Analytical Testing Center is located in Medicilon Nanhui Park, with a total analytical laboratory area of 2800 square meters. The established GMP system has passed NMPA on-site inspections and actively promotes CNAS certification.

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...